Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 363-369 , May 2009

Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer

  • Samira Rasaneh

      Affiliations

    • Department of Medical Physics, Tarbiat Modares University, Tehran, Iran
    • ,
  • Hossein Rajabi

      Affiliations

    • Department of Medical Physics, Tarbiat Modares University, Tehran, Iran
    • Corresponding Author InformationCorresponding author. Tel.: +98 21 82883894; fax: +98 21 88006544.
    • ,
  • Mohammad Hossein Babaei

      Affiliations

    • Department of Radioisotope, Nuclear Science and Technology Research Institute, Tehran, Iran
    • ,
  • Fariba Johari Daha

      Affiliations

    • Department of Radioisotope, Nuclear Science and Technology Research Institute, Tehran, Iran
    • ,
  • Mojtaba Salouti

      Affiliations

    • Department of Biology, School of Sciences, Islamic Azad University - Zanjan Branch, Zanjan, Iran

Received 20 October 2008 ,Revised 18 January 2009 ,Accepted 31 January 2009.

References 

  1. Metro G, Mottolese M, Fabi A. HER-2-Positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother. 2008;9:2583–2601
  2. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med. 2001;7:548–552
  3. Agrawal A, Gutteridge E, Gee J, Nicholson R, Robertson JR. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer. 2005;12:s135–s144
  4. Nahta R, Esteva F. HER-2-Targeted therapy — lessons learned and future directions. Clin Cancer Res. 2003;9:5078–5084
  5. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253–268
  6. Hooge ML-d, Kosterink J, Patrick P, Nijnuis H, Tran L, Bart J, et al. Preclinical characterisation of 111In–DTPA–trastuzumab. Br J Pharmacol. 2004;143:99–106
  7. Costantini D, Chan C, Cai Z, Vallis K, Reilly R. (111)In-Labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48:1357–1368
  8. Li G, Wang Y, Huang K, Zhang H, Peng W, Zhang C. The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin. Nucl Med Biol. 2005;32:59–65
  9. Nayak D, Lahiri S. Application of radioisotopes in the field of nuclear medicine. J Radioanal Nucl Chem. 1999;42:423–432
  10. Yordanov A, Hens M, Pegram C, Bigner D, Zalutsky M. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol. 2007;34:173–183
  11. Mohsin H, Fitzsimmons J, Shelton T, Hoffman T, Cutler C, Lewis M, et al. Preparation and biological evaluation of 111In, 177Lu and 90Y labeled DOTA analogues conjugated to B72.3. Nucl Med Biol. 2007;34:493–502
  12. Lewis M, Kao J, Anderson A, Shively J, Raubitschek A. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconjug Chem. 2001;12:320–324
  13. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PJ. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77–89
  14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63
  15. Ménard S, Pupa S, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003;22:6570–6578
  16. Tan A, Swain S. Ongoing adjuvant trials with trastuzumab in breast cancer. Semi Oncol. 2003;30:54–64
  17. Seidman A, Hudis C, Pierri M, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221
  18. Fleck L. The costs of caring: Who pays? Who profits? Who panders?. Hastings Cent Rep. 2006;36:13–17
  19. Vallabhajosula S, Kuji I, Hamacher K, Konishi S, Kostakoglu L, Kothari P, et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?. J Nucl Med. 2005;46:634–641
  20. Vallabhajosula S, Goldsmith S, Hamacher K, Kostakoglu L, Konishi S, Milowski M, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46:850–858
  21. Borchardt P, Yuan R, Miederer M, McDevitt M, Scheinberg D. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res. 2003;63:5084–5090

PII: S0969-8051(09)00039-0

doi: 10.1016/j.nucmedbio.2009.01.015

Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 363-369 , May 2009

Article Tools

* Image Usage & Resolution